Ventilator-associated pneumonia after traumatic brain injury: a timing-sensitive ecological framework of neuroimmune–pulmonary vulnerability

Ventilator-associated pneumonia (VAP) is frequent after traumatic brain injury (TBI), but its biological meaning and outcome impact remain incompletely defined. Traditional models emphasise mechanical ventilation, aspiration, colonisation, endotracheal tube biofilm, and hospital pathogens. These mechanisms remain essential, but they do not fully explain the early clustering, heterogeneous susceptibility, changing bacteriology, and variable mortality effect observed after TBI. Severe brain injury creates an early vulnerable host state through impaired consciousness and airway protection, neuroimmune dysregulation, autonomic and endocrine activation, altered pulmonary immune surveillance, and, in many patients, extracranial trauma, shock, transfusion, or thoracic injury. These processes interact with ventilation, antibiotic pressure, and rapid respiratory microbiome disruption. Early VAP may reflect abrupt loss of control after injury and intubation, whereas late VAP may reflect persistent or secondary failure driven by biofilm maturation, antibiotic selection, multidrug-resistant pathogens, and intensive care unit (ICU)-acquired immune dysfunction. Clinically, VAP consistently prolongs ventilation, ICU stay, antibiotic exposure, and resource use, while its independent effect on mortality is phenotype- and context-dependent. This model proposes a timing-sensitive ecological framework in which established mechanisms may converge early and with particular clinical intensity after severe TBI, creating a vulnerable host-microbe state that may lower the threshold for clinically apparent infection. Future studies should distinguish isolated TBI from polytrauma, compare TBI with other acute brain injuries and non-neurological ventilated populations, and incorporate dynamic immune, microbial, and trajectory-based outcomes. VAP after TBI should be viewed as a timing-sensitive interaction between ventilator exposure and early host vulnerability, not as a distinct disease entity or as a pneumonia pathway unique to traumatic brain injury. The TBI-focused contribution lies in the early convergence of otherwise non-unique mechanisms: impaired airway control, aspiration risk, neuroimmune-endocrine activation, treatment exposure, dysbiosis, and extracranial injury burden, rather than in any single TBI-specific mechanism. Isolated TBI and TBI with polytrauma are biologically different phenotypes and should be separated in future studies. Early and late VAP may represent different phases of loss of pulmonary host–microbe containment; this distinction is probabilistic rather than TBI-specific in itself and requires validation in TBI-stratified cohorts. Mortality remains clinically relevant but context-dependent; VAP more consistently modifies recovery trajectory, ventilator dependence, ICU stay, antibiotic exposure, and possibly neurological recovery.